[144] Supernus Pharmaceuticals, Inc. SEC Filing
Supernus Pharmaceuticals (SUPN) filed a Form 144 notifying a proposed sale of 14,000 common shares. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ with an approximate aggregate market value of $623,070, representing part of the company's 56,073,088 shares outstanding. The filing shows the shares were acquired and will be sold on 08/25/2025 following an exercise of options under a registered plan and were paid for in cash on that date. The filer reports no securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Supernus Pharmaceuticals (SUPN) ha depositato il Modulo 144 notificando la proposta di vendita di 14.000 azioni ordinarie. Le azioni saranno vendute tramite Morgan Stanley Smith Barney LLC sul NASDAQ per un valore di mercato aggregato approssimativo di $623.070, rappresentando una quota delle 56.073.088 azioni in circolazione della societ脿. Il deposito indica che le azioni sono state acquisite e verranno vendute il 25/08/2025 a seguito di un esercizio di opzioni nell'ambito di un piano registrato e sono state pagate in contanti in quella data. Il dichiarante segnala di non aver venduto titoli negli ultimi tre mesi. L鈥檃vviso contiene la consueta dichiarazione secondo cui il venditore non 猫 a conoscenza di informazioni materiali sfavorevoli non divulgate.
Supernus Pharmaceuticals (SUPN) present贸 el Formulario 144 notificando una propuesta de venta de 14.000 acciones ordinarias. Las acciones se vender谩n a trav茅s de Morgan Stanley Smith Barney LLC en NASDAQ por un valor de mercado agregado aproximado de $623.070, representando parte de las 56.073.088 acciones en circulaci贸n de la compa帽铆a. La presentaci贸n indica que las acciones fueron adquiridas y se vender谩n el 25/08/2025 tras un ejercicio de opciones bajo un plan registrado y se pagaron en efectivo en esa fecha. El declarante informa que no ha vendido valores en los 煤ltimos tres meses. El aviso incluye la representaci贸n est谩ndar de que el vendedor no conoce informaci贸n adversa material no divulgada.
鞀堩嵓雱堨姢 韺岆鞀堩嫲旎姢(SUPN)電� 氤错喌欤� 14,000欤� 毵り皝 鞓堨爼鞛勳潉 韱奠頃橂姅 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 鞎� 齑濎嫓鞛リ皜旃� $623,070鞐� 毵り皝霅� 鞓堨爼鞚措┌, 鞚措姅 須岇偓鞚� 氚滍枆欤检嫕靾� 56,073,088欤检潣 鞚茧秬鞐� 頃措嫻頃╇媹雼�. 鞝滌稖靹滊鞐� 霐半ゴ氅� 頃措嫻 欤检嫕鞚� 旆摑霅橃棃瓿� 2025-08-25鞐� 霌彪霅� 頂岆灉鞐� 霐半ジ 鞓奠厴 頄夓偓 鞚错泟 毵り皝霅� 鞓堨爼鞚措┌, 攴� 雮犾鞐� 順勱笀鞙茧 雽�旮堨澊 歆�旮夒悩鞐堨姷雼堧嫟. 鞝滌稖鞛愲姅 歆�雮� 3臧滌洈臧� 毵る弰頃� 歃濌秾鞚� 鞐嗢棃雼�瓿� 氤搓碃頄堨姷雼堧嫟. 韱奠靹滌棎電� 毵る弰鞚胳澊 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 韱奠儊鞝侅澑 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Supernus Pharmaceuticals (SUPN) a d茅pos茅 un formulaire 144 notifant la vente propos茅e de 14 000 actions ordinaires. Les actions doivent 锚tre vendues par l'interm茅diaire de Morgan Stanley Smith Barney LLC sur le NASDAQ pour une valeur marchande agr茅g茅e approximative de 623 070 $, repr茅sentant une partie des 56 073 088 actions en circulation de la soci茅t茅. Le d茅p么t indique que les actions ont 茅t茅 acquises et seront vendues le 25/08/2025 suite 脿 un exercice d'options dans le cadre d'un plan enregistr茅 et ont 茅t茅 pay茅es en esp猫ces 脿 cette date. Le d茅clarant signale aucune vente de titres au cours des trois derniers mois. L'avis inclut la d茅claration habituelle selon laquelle le vendeur n'a pas connaissance d'informations d茅favorables mat茅rielles non divulgu茅es.
Supernus Pharmaceuticals (SUPN) hat ein Formular 144 eingereicht und den geplanten Verkauf von 14.000 Stammaktien angezeigt. Die Aktien sollen 眉ber Morgan Stanley Smith Barney LLC an der NASDAQ zum ungef盲hren Gesamtmarktwert von $623.070 verkauft werden und stellen einen Teil der 56.073.088 ausstehenden Aktien des Unternehmens dar. Die Einreichung besagt, dass die Aktien erworben wurden und am 25.08.2025 nach einem Aus眉ben von Optionen im Rahmen eines registrierten Plans verkauft werden sollen und an diesem Datum in bar bezahlt wurden. Der Einreicher berichtet, dass in den letzten drei Monaten keine Wertpapiere verkauft wurden. Die Mitteilung enth盲lt die 眉bliche Zusicherung, dass dem Verk盲ufer keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.
- Transparent regulatory compliance鈥攖he filer disclosed the proposed sale under Rule 144 through a listed broker
- No prior sales in the past three months, reducing aggregated-sale complexity under Rule 144
- Securities acquired via exercise under a registered plan and paid in cash, indicating standard compensation mechanics
- None.
Insights
TL;DR: Officer/insider intends to sell recently exercised shares worth $623k, a routine liquidity event disclosed under Rule 144.
The Form 144 documents a proposed sale of 14,000 common shares acquired and paid for on 08/25/2025 via option exercise under a registered plan. The sale is routed through Morgan Stanley Smith Barney on NASDAQ and equals an aggregate market value of $623,070 against 56,073,088 shares outstanding. As disclosed, there were no other sales in the prior three months. This filing is procedural disclosure required for restricted/controlled securities and, based solely on the filing, indicates a routine insider liquidity event rather than a material corporate development.
TL;DR: The filing reflects compliance with Rule 144 and confirms no recent aggregated sales, signaling orderly insider selling.
The notice specifies the shares arose from exercising options under a registered plan and were paid in cash on the acquisition date, suggesting an approved compensation exercise. The seller affirms no undisclosed material adverse information. The absence of prior three-month sales reduces aggregation concerns under Rule 144. From a governance perspective, the filing documents transparency around insider disposition consistent with regulatory requirements.
Supernus Pharmaceuticals (SUPN) ha depositato il Modulo 144 notificando la proposta di vendita di 14.000 azioni ordinarie. Le azioni saranno vendute tramite Morgan Stanley Smith Barney LLC sul NASDAQ per un valore di mercato aggregato approssimativo di $623.070, rappresentando una quota delle 56.073.088 azioni in circolazione della societ脿. Il deposito indica che le azioni sono state acquisite e verranno vendute il 25/08/2025 a seguito di un esercizio di opzioni nell'ambito di un piano registrato e sono state pagate in contanti in quella data. Il dichiarante segnala di non aver venduto titoli negli ultimi tre mesi. L鈥檃vviso contiene la consueta dichiarazione secondo cui il venditore non 猫 a conoscenza di informazioni materiali sfavorevoli non divulgate.
Supernus Pharmaceuticals (SUPN) present贸 el Formulario 144 notificando una propuesta de venta de 14.000 acciones ordinarias. Las acciones se vender谩n a trav茅s de Morgan Stanley Smith Barney LLC en NASDAQ por un valor de mercado agregado aproximado de $623.070, representando parte de las 56.073.088 acciones en circulaci贸n de la compa帽铆a. La presentaci贸n indica que las acciones fueron adquiridas y se vender谩n el 25/08/2025 tras un ejercicio de opciones bajo un plan registrado y se pagaron en efectivo en esa fecha. El declarante informa que no ha vendido valores en los 煤ltimos tres meses. El aviso incluye la representaci贸n est谩ndar de que el vendedor no conoce informaci贸n adversa material no divulgada.
鞀堩嵓雱堨姢 韺岆鞀堩嫲旎姢(SUPN)電� 氤错喌欤� 14,000欤� 毵り皝 鞓堨爼鞛勳潉 韱奠頃橂姅 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 鞎� 齑濎嫓鞛リ皜旃� $623,070鞐� 毵り皝霅� 鞓堨爼鞚措┌, 鞚措姅 須岇偓鞚� 氚滍枆欤检嫕靾� 56,073,088欤检潣 鞚茧秬鞐� 頃措嫻頃╇媹雼�. 鞝滌稖靹滊鞐� 霐半ゴ氅� 頃措嫻 欤检嫕鞚� 旆摑霅橃棃瓿� 2025-08-25鞐� 霌彪霅� 頂岆灉鞐� 霐半ジ 鞓奠厴 頄夓偓 鞚错泟 毵り皝霅� 鞓堨爼鞚措┌, 攴� 雮犾鞐� 順勱笀鞙茧 雽�旮堨澊 歆�旮夒悩鞐堨姷雼堧嫟. 鞝滌稖鞛愲姅 歆�雮� 3臧滌洈臧� 毵る弰頃� 歃濌秾鞚� 鞐嗢棃雼�瓿� 氤搓碃頄堨姷雼堧嫟. 韱奠靹滌棎電� 毵る弰鞚胳澊 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 韱奠儊鞝侅澑 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Supernus Pharmaceuticals (SUPN) a d茅pos茅 un formulaire 144 notifant la vente propos茅e de 14 000 actions ordinaires. Les actions doivent 锚tre vendues par l'interm茅diaire de Morgan Stanley Smith Barney LLC sur le NASDAQ pour une valeur marchande agr茅g茅e approximative de 623 070 $, repr茅sentant une partie des 56 073 088 actions en circulation de la soci茅t茅. Le d茅p么t indique que les actions ont 茅t茅 acquises et seront vendues le 25/08/2025 suite 脿 un exercice d'options dans le cadre d'un plan enregistr茅 et ont 茅t茅 pay茅es en esp猫ces 脿 cette date. Le d茅clarant signale aucune vente de titres au cours des trois derniers mois. L'avis inclut la d茅claration habituelle selon laquelle le vendeur n'a pas connaissance d'informations d茅favorables mat茅rielles non divulgu茅es.
Supernus Pharmaceuticals (SUPN) hat ein Formular 144 eingereicht und den geplanten Verkauf von 14.000 Stammaktien angezeigt. Die Aktien sollen 眉ber Morgan Stanley Smith Barney LLC an der NASDAQ zum ungef盲hren Gesamtmarktwert von $623.070 verkauft werden und stellen einen Teil der 56.073.088 ausstehenden Aktien des Unternehmens dar. Die Einreichung besagt, dass die Aktien erworben wurden und am 25.08.2025 nach einem Aus眉ben von Optionen im Rahmen eines registrierten Plans verkauft werden sollen und an diesem Datum in bar bezahlt wurden. Der Einreicher berichtet, dass in den letzten drei Monaten keine Wertpapiere verkauft wurden. Die Mitteilung enth盲lt die 眉bliche Zusicherung, dass dem Verk盲ufer keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.
FAQ
What does Supernus (SUPN) Form 144 filed on 08/25/2025 disclose?
Why was a Form 144 filed for SUPN shares?
How many SUPN shares are outstanding and what portion does this sale represent?
Were any SUPN securities sold by this person in the past three months?
What broker will handle the SUPN share sale?
